David Zhen

Associate Professor of Medicine

Montefiore Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Zhen is an Associate Professor of Medicine at UW Medical Center - Montlake, USA. His research primarily focuses on pancreatic cancer and its treatment modalities, including chemotherapy, immunotherapy, and molecular testing. He has contributed to several recent publications addressing refractory solid tumors, chemotherapy-associated neuropathy, and genetic mutations impacting survival outcomes in cancer patients.

Articles (10)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (2)

Stacey Cohen

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Thomas Enzler

University of Michigan

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Zhen

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers

Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.

Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study.

The role of molecular testing in pancreatic cancer.

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.

Combination immunotherapy for pancreatic cancer: challenges and future considerations.

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.

DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma.

Collaborators (2)

Stacey Cohen

Thomas Enzler

Make your next move.